Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma (NAMS) Equity Average (2023 - 2025)

NewAmsterdam Pharma's Equity Average history spans 3 years, with the latest figure at $705.8 million for Q4 2025.

  • For Q4 2025, Equity Average rose 24.21% year-over-year to $705.8 million; the TTM value through Dec 2025 reached $705.8 million, up 24.21%, while the annual FY2025 figure was $720.5 million, 37.77% up from the prior year.
  • Equity Average for Q4 2025 was $705.8 million at NewAmsterdam Pharma, down from $753.3 million in the prior quarter.
  • Across five years, Equity Average topped out at $777.9 million in Q2 2025 and bottomed at $310.1 million in Q4 2023.
  • The 3-year median for Equity Average is $423.0 million (2023), against an average of $516.7 million.
  • The largest annual shift saw Equity Average decreased 21.57% in 2024 before it surged 119.2% in 2025.
  • A 3-year view of Equity Average shows it stood at $310.1 million in 2023, then soared by 83.22% to $568.2 million in 2024, then increased by 24.21% to $705.8 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Equity Average are $705.8 million (Q4 2025), $753.3 million (Q3 2025), and $777.9 million (Q2 2025).